Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 28 of 32.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next»
    EudraCT Number: 2011-000926-31 Sponsor Protocol Number: GWMS1137 Start Date*: 2011-06-29
    Sponsor Name:GW Pharma Ltd.
    Full Title: A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to...
    Medical condition: Spasticity in multiple sclerosis (MS).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-002560-34 Sponsor Protocol Number: F1J-US-HMFR(b) Start Date*: 2008-09-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
    Medical condition: Central neuropathic pain due to Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007162-32 Sponsor Protocol Number: RMaIDSM Start Date*: 2007-10-30
    Sponsor Name:ISTITUTO C. MONDINO
    Full Title: ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 Nervous system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011888-37 Sponsor Protocol Number: CZOL446HDE40 Start Date*: 2010-07-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multip...
    Medical condition: osteoporosis in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000638-75 Sponsor Protocol Number: TG1101-RMS301 Start Date*: 2017-12-05
    Sponsor Name:TG Therapeutics
    Full Title: Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10029202 Nervous system disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000507-44 Sponsor Protocol Number: D-FR-52120-223 Start Date*: 2016-06-29
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018273-38 Sponsor Protocol Number: D1950C00011 Start Date*: 2010-03-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dos...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005606-30 Sponsor Protocol Number: CAM-THY Start Date*: 2012-04-25
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY
    Medical condition: This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10058948 Nephritis autoimmune PT
    14.1 10014698 - Endocrine disorders 10049046 Autoimmune thyroiditis PT
    14.1 10021428 - Immune system disorders 10061664 Autoimmune disorder PT
    14.1 10014698 - Endocrine disorders 10068004 Autoimmune hyperthyroidism LLT
    14.1 10005329 - Blood and lymphatic system disorders 10050245 Autoimmune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004980-39 Sponsor Protocol Number: Amiloride02 Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000579-19 Sponsor Protocol Number: MAGNET Start Date*: 2021-06-25
    Sponsor Name:Stichting TRICALS Foundation
    Full Title: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002628-34 Sponsor Protocol Number: thorp8617-1 Start Date*: 2012-08-29
    Sponsor Name:Thor Petersen
    Full Title: Optic neuritis and early treatment with methylprednisolone.
    Medical condition: Optic neuritis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10030946 Optic neuritis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019519-39 Sponsor Protocol Number: RAPIT Start Date*: 2012-03-14
    Sponsor Name:Erasmus MC - Department of Neurology
    Full Title: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial)
    Medical condition: Tuberous Sclerosis Complex
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006299-39 Sponsor Protocol Number: 191622-082-01 Start Date*: 2008-04-23
    Sponsor Name:Allergan
    Full Title: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...
    Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046543 Urinary incontinence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005576-18 Sponsor Protocol Number: CCNP520X2102 Start Date*: 2015-08-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly su...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002258-30 Sponsor Protocol Number: M/SATIVX/01 Start Date*: 2011-10-04
    Sponsor Name:ALMIRALL PRODESFARMA
    Full Title: NEUROPHYSIOLOGIC STUDY AIMED AT EVALUATING ON EFFECT OF SATIVEX® ON SPASTICITY IN PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: Subject of both male and female gender affected by Secondary-Progressive (SP) or Primary-Progressive (PP) MS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006257-40 Sponsor Protocol Number: ACI-24-0701 Start Date*: 2009-12-09
    Sponsor Name:AC Immune SA
    Full Title: A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Dis...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-005262-39 Sponsor Protocol Number: 2006-2209 Start Date*: 2007-05-30
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Flupirtin as Oral Treatment in MS
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005523-42 Sponsor Protocol Number: 905-EC-005 Start Date*: 2007-09-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ...
    Medical condition: Neurogenic detrusor overactivity.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003068-47 Sponsor Protocol Number: UROBOTOX 1 Start Date*: 2005-09-22
    Sponsor Name:Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken
    Full Title: Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning
    Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 14:57:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA